| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate |
2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111909267-B |
| titleOfInvention |
Low-immunogenicity anti-TNF-alpha humanized monoclonal antibody TCX063 and its application |
| abstract |
The invention relates to the field of biotechnology, in particular to a low-immunogenicity anti-TNF-alpha humanized monoclonal antibody TCX063 and application thereof. The present invention provides an anti-TNF- α humanized monoclonal antibody TCX063 which is an anti-TNF- α humanized monoclonal antibody reduced in immunogenicity obtained by modifying the FR region of inflixb monoclonal antibody. The antibody provided by the invention has the same TNF-alpha antigen binding site as an inflixb monoclonal antibody, retains the antigen affinity and specificity of the inflixb monoclonal antibody, but has immunogenicity remarkably lower than that of the inflixb monoclonal antibody. The low-immunogenicity TNF-alpha antibody can reduce the risk of side effects of the drug caused by immune reaction caused by the immunogenicity of the antibody in a human body; reduces the antibody drug ADA; the in vivo half-life of the antibody is prolonged; meanwhile, the subcutaneous drug delivery mode becomes possible, and the application potential and the value are great. |
| priorityDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |